{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:42:35Z","timestamp":1792190555972,"version":"4.4.0"},"reference-count":89,"publisher":"American Association for the Advancement of Science (AAAS)","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T00:00:00Z","timestamp":1652313600000},"content-version":"vor","delay-in-days":131,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32071156"],"award-info":[{"award-number":["32071156"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170650"],"award-info":[{"award-number":["32170650"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["csbj.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Comput Struct Biotechnol J"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.csbj.2022.05.019","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T18:14:48Z","timestamp":1652724888000},"page":"2391-2401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunction"],"prefix":"10.34133","volume":"20","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[{"name":"Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Zang","sequence":"additional","affiliation":[{"name":"Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianda","family":"Fan","sequence":"additional","affiliation":[{"name":"Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaochen","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anzi","family":"Li","sequence":"additional","affiliation":[{"name":"BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[{"name":"BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Wang","sequence":"additional","affiliation":[{"name":"BGI Education Center, University of Chinese Academy of Sciences, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongsheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Genomic Medicine, Wenzhou Medical University, Wenzhou, China"},{"name":"Beijing Institutes of Life Science, Chinese Academy of Sciences, Beijing, China"},{"name":"IBMC-BGI Center, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajing","family":"Teng","sequence":"additional","affiliation":[{"name":"Key laboratory of Carcinogenesis and Translational Research (Ministry of Education\/Beijing), Department of Radiation Oncology, Peking University Cancer Hospital & Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0367"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2214"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0402"},{"key":"e_1_3_4_5_2","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1001\/jamaoncol.2016.1051","article-title":"Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review","volume":"2","author":"Friedman C.F.","year":"2016","unstructured":"Friedman C.F., Proverbs-Singh T.A. and Postow M.A.: Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review. JAMA Oncol 2016; 2: 1346.","journal-title":"JAMA Oncol"},{"key":"e_1_3_4_6_2","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/jnci\/djab035","article-title":"Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy","volume":"113","author":"Jing Y.","year":"2021","unstructured":"Jing Y., Zhang Y., Wang J., Li K., Chen X. et al: Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. J Natl Cancer Inst 2021; 113: 1396.","journal-title":"J Natl Cancer Inst"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00557-3"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.3109\/0284186X.2011.602109"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.007"},{"key":"e_1_3_4_13_2","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/bjc.2013.597","article-title":"Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study","volume":"109","author":"Chen Y.K.","year":"2013","unstructured":"Chen Y.K., Lin C.L., Cheng F.T., Sung F.C. and Kao C.H.: Cancer risk in patients with Hashimoto's thyroiditis: a nationwide cohort study. Br J Cancer 2013; 109: 2496.","journal-title":"Br J Cancer"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"e_1_3_4_15_2","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.7150\/thno.26862","article-title":"Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma","volume":"8","author":"Teng H.","year":"2018","unstructured":"Teng H., Mao F., Liang J., Xue M., Wei W. et al: Transcriptomic signature associated with carcinogenesis and aggressiveness of papillary thyroid carcinoma. Theranostics 2018; 8: 4345.","journal-title":"Theranostics"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.5005"},{"key":"e_1_3_4_17_2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer","volume":"33","author":"Xing M.","year":"2015","unstructured":"Xing M., Alzahrani A.S., Carson K.A., Shong Y.K., Kim T.Y. et al: Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015; 33: 42.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_18_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40425-018-0483-y","article-title":"Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer","volume":"7","author":"Imam S.","year":"2019","unstructured":"Imam S., Dar P., Paparodis R., Almotah K., Al-Khudhair A. et al: Nature of coexisting thyroid autoimmune disease determines success or failure of tumor immunity in thyroid cancer. J Immunother Cancer 2019; 7: 3.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_19_2","doi-asserted-by":"crossref","first-page":"e2118526","DOI":"10.1001\/jamanetworkopen.2021.18526","article-title":"Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes","volume":"4","author":"Xu S.","year":"2021","unstructured":"Xu S., Huang H., Qian J., Liu Y., Huang Y. et al: Prevalence of Hashimoto Thyroiditis in Adults With Papillary Thyroid Cancer and Its Association With Cancer Recurrence and Outcomes. JAMA Netw Open 2021; 4: e2118526.","journal-title":"JAMA Netw Open"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1530\/EJE-12-0903","article-title":"The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis","volume":"168","author":"Lee J.H.","year":"2013","unstructured":"Lee J.H., Kim Y., Choi J.W. and Kim Y.S.: The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis. Eur J Endocrinol 2013; 168: 343.","journal-title":"Eur J Endocrinol"},{"key":"e_1_3_4_21_2","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s12253-019-00580-w","article-title":"Thyroid Carcinoma Coexisting with Hashimoto's Thyreoiditis: Clinicopathological and Molecular Characteristics Clue up Pathogenesis","volume":"25","author":"Molnar C.","year":"2019","unstructured":"Molnar C., Molnar S., Bedekovics J., Mokanszki A., Gyory F. et al: Thyroid Carcinoma Coexisting with Hashimoto's Thyreoiditis: Clinicopathological and Molecular Characteristics Clue up Pathogenesis. Pathol Oncol Res 2019; 25: 1191.","journal-title":"Pathol Oncol Res"},{"key":"e_1_3_4_22_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10147-014-0754-7","article-title":"Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?","volume":"20","author":"Kwak H.Y.","year":"2015","unstructured":"Kwak H.Y., Chae B.J., Eom Y.H., Hong Y.R., Seo J.B. et al: Does papillary thyroid carcinoma have a better prognosis with or without Hashimoto thyroiditis?. Int J Clin Oncol 2015; 20: 463.","journal-title":"Int J Clin Oncol"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-1309"},{"key":"e_1_3_4_24_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00423-012-1021-x","article-title":"Coexistence of papillary thyroid cancer with Hashimoto thyroiditis","volume":"398","author":"Konturek A.","year":"2013","unstructured":"Konturek A., Barczynski M., Wierzchowski W., Stopa M. and Nowak W.: Coexistence of papillary thyroid cancer with Hashimoto thyroiditis. Langenbecks Arch Surg 2013; 398: 389.","journal-title":"Langenbecks Arch Surg"},{"key":"e_1_3_4_25_2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1530\/ERC-17-0085","article-title":"Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer","volume":"24","author":"Marotta V.","year":"2017","unstructured":"Marotta V., Sciammarella C., Chiofalo M.G., Gambardella C., Bellevicine C. et al: Hashimoto's thyroiditis predicts outcome in intrathyroidal papillary thyroid cancer. Endocr Relat Cancer 2017; 24: 485.","journal-title":"Endocr Relat Cancer"},{"key":"e_1_3_4_26_2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1530\/ERC-15-0408","article-title":"Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma","volume":"23","author":"Kim S.K.","year":"2016","unstructured":"Kim S.K., Woo J.W., Lee J.H., Park I., Choe J.H. et al: Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma. Endocr Relat Cancer 2016; 23: 27.","journal-title":"Endocr Relat Cancer"},{"key":"e_1_3_4_27_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s12022-011-9164-9","article-title":"Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence","volume":"22","author":"Huang B.Y.","year":"2011","unstructured":"Huang B.Y., Hseuh C., Chao T.C., Lin K.J. and Lin J.D.: Well-differentiated thyroid carcinoma with concomitant Hashimoto's thyroiditis present with less aggressive clinical stage and low recurrence. Endocr Pathol 2011; 22: 144.","journal-title":"Endocr Pathol"},{"key":"e_1_3_4_28_2","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N : Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014; 159: 676.","journal-title":"Cell"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","first-page":"e1006239","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers","volume":"12","author":"Yoo S.K.","year":"2016","unstructured":"Yoo S.K., Lee S., Kim S.J., Jee H.G., Kim B.A. et al: Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers. PLoS Genet 2016; 12: e1006239.","journal-title":"PLoS Genet"},{"key":"e_1_3_4_30_2","first-page":"e411","article-title":"An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics","volume":"173","author":"Liu J.","year":"2018","unstructured":"Liu J., Lichtenberg T., Hoadley K.A., Poisson L.M., Lazar A.J. et al: An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell 2018; 173: e411.","journal-title":"Cell"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1136\/ebmental-2019-300117"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw377"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337"},{"key":"e_1_3_4_36_2","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26476","article-title":"Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data","volume":"6","author":"Racle J.","year":"2017","unstructured":"Racle J., de Jonge K., Baumgaertner P., Speiser D.E. and Gfeller D.: Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data. Elife 2017; 6.","journal-title":"Elife"},{"key":"e_1_3_4_37_2","article-title":"Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression","volume":"17","author":"Becht E.","year":"2016","unstructured":"Becht E., Giraldo N.A., Lacroix L., Buttard B., Elarouci N. et al: Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol 2016; 17.","journal-title":"Genome Biol"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0638-6"},{"key":"e_1_3_4_39_2","doi-asserted-by":"crossref","first-page":"1902880","DOI":"10.1002\/advs.201902880","article-title":"ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy","volume":"7","author":"Miao Y.R.","year":"2020","unstructured":"Miao Y.R., Zhang Q., Lei Q., Luo M., Xie G.Y. et al: ImmuCellAI: A Unique Method for Comprehensive T-Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy. Adv Sci (Weinh) 2020; 7: 1902880.","journal-title":"Adv Sci (Weinh)"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7"},{"key":"e_1_3_4_41_2","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.758339","article-title":"Papillary Thyroid Carcinoma Landscape and Its Immunological Link With Hashimoto Thyroiditis at Single-Cell Resolution","volume":"9","author":"Pan J.","year":"2021","unstructured":"Pan J., Ye F., Yu C., Zhu Q., Li J. et al: Papillary Thyroid Carcinoma Landscape and Its Immunological Link With Hashimoto Thyroiditis at Single-Cell Resolution. Front Cell Dev Biol 2021; 9: 758339.","journal-title":"Front Cell Dev Biol"},{"key":"e_1_3_4_42_2","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.649863","article-title":"Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management","volume":"12","author":"Zhan L.","year":"2021","unstructured":"Zhan L., Feng H.F., Liu H.Q., Guo L.T., Chen C. et al: Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management. Front Endocrinol (Lausanne) 2021; 12: 649863.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"e_1_3_4_43_2","doi-asserted-by":"crossref","first-page":"e814","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer","volume":"48","author":"Thorsson V.","year":"2018","unstructured":"Thorsson V., Gibbs D.L., Brown S.D., Wolf D., Bortone D.S. et al: The Immune Landscape of Cancer. Immunity 2018; 48: e814.","journal-title":"Immunity"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18742-9"},{"key":"e_1_3_4_45_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13000-015-0346-5","article-title":"Clinicopathological features of recurrent papillary thyroid cancer","volume":"10","author":"Zhu J.","year":"2015","unstructured":"Zhu J., Wang X., Zhang X., Li P. and Hou H.: Clinicopathological features of recurrent papillary thyroid cancer. Diagn Pathol 2015; 10: 96.","journal-title":"Diagn Pathol"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13475"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/coa.12520"},{"key":"e_1_3_4_48_2","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/j.1365-2265.2009.03699.x","article-title":"The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies","volume":"72","author":"Muzza M.","year":"2010","unstructured":"Muzza M., Degl'Innocenti D., Colombo C., Perrino M., Ravasi E. et al: The tight relationship between papillary thyroid cancer, autoimmunity and inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 2010; 72: 702.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"e_1_3_4_49_2","doi-asserted-by":"crossref","first-page":"10651","DOI":"10.1038\/s41598-020-67615-0","article-title":"Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis","volume":"10","author":"Mohamed S.Y.","year":"2020","unstructured":"Mohamed S.Y., Ibrahim T.R., Elbasateeny S.S., Abdelaziz L.A., Farouk S. et al: Clinicopathological characterization and prognostic implication of FOXP3 and CK19 expression in papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis. Sci Rep 2020; 10: 10651.","journal-title":"Sci Rep"},{"key":"e_1_3_4_50_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.14639\/0392-100X-1709","article-title":"Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients","volume":"37","author":"Liang J.","year":"2017","unstructured":"Liang J., Zeng W., Fang F., Yu T., Zhao Y. et al: Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients. Acta Otorhinolaryngol Ital 2017; 37: 393.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"e_1_3_4_51_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4174\/jkss.2013.85.1.20","article-title":"Papillary thyroid carcinoma with thyroiditis: lymph node metastasis, complications","volume":"85","author":"Kim Y.S.","year":"2013","unstructured":"Kim Y.S., Choi H.J. and Kim E.S.: Papillary thyroid carcinoma with thyroiditis: lymph node metastasis, complications. J Korean Surg Soc 2013; 85: 20.","journal-title":"J Korean Surg Soc"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03537.x"},{"key":"e_1_3_4_53_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s002680020165","article-title":"Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited","volume":"25","author":"Kebebew E.","year":"2001","unstructured":"Kebebew E., Treseler P.A., Ituarte P.H. and Clark O.H.: Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg 2001; 25: 632.","journal-title":"World J Surg"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2012.27.8.883"},{"key":"e_1_3_4_55_2","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijsu.2015.12.059","article-title":"Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome","volume":"28","author":"Dobrinja C.","year":"2016","unstructured":"Dobrinja C., Makovac P., Pastoricchio M., Cipolat Mis T., Bernardi S. et al: Coexistence of chronic lymphocytic thyroiditis and papillary thyroid carcinoma. Impact on presentation, management, and outcome. Int J Surg 2016; 28 Suppl 1: S70.","journal-title":"Int J Surg"},{"key":"e_1_3_4_56_2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000486367","article-title":"Effects of Chronic Lymphocytic Thyroiditis on the Clinicopathological Features of Papillary Thyroid Cancer","volume":"7","author":"Babli S.","year":"2018","unstructured":"Babli S., Payne R.J., Mitmaker E. and Rivera J.: Effects of Chronic Lymphocytic Thyroiditis on the Clinicopathological Features of Papillary Thyroid Cancer. Eur Thyroid J 2018; 7: 95.","journal-title":"Eur Thyroid J"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01323-8"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03752-4"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921445117"},{"key":"e_1_3_4_61_2","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.7150\/thno.50333","article-title":"From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer","volume":"11","author":"D'Andrea G.","year":"2021","unstructured":"D'Andrea G., Lassalle S., Guevara N., Mograbi B. and Hofman P.: From biomarkers to therapeutic targets: the promise of PD-L1 in thyroid autoimmunity and cancer. Theranostics 2021; 11: 1310.","journal-title":"Theranostics"},{"key":"e_1_3_4_62_2","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han Y.","year":"2020","unstructured":"Han Y., Liu D. and Li L.: PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res 2020; 10: 727.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.04.003"},{"key":"e_1_3_4_64_2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity","volume":"103","author":"Alvarez-Sierra D.","year":"2019","unstructured":"Alvarez-Sierra D., Marin-Sanchez A., Ruiz-Blazquez P., de Jesus G.C., Iglesias-Felip C. et al: Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity. J Autoimmun 2019; 103: 102285.","journal-title":"J Autoimmun"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0409"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30616-2"},{"key":"e_1_3_4_67_2","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"37","author":"Chung H.C.","year":"2019","unstructured":"Chung H.C., Ros W., Delord J.P., Perets R., Italiano A. et al: Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 2019; 37: 1470.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_68_2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen E.E.W.","year":"2019","unstructured":"Cohen E.E.W., Soulieres D., Le Tourneau C., Dinis J., Licitra L. et al: Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 2019; 393: 156.","journal-title":"Lancet"},{"key":"e_1_3_4_69_2","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab","volume":"101","author":"de Filette J.","year":"2016","unstructured":"de Filette J., Jansen Y., Schreuer M., Everaert H., Velkeniers B. et al: Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab. J Clin Endocrinol Metab 2016; 101: 4431.","journal-title":"J Clin Endocrinol Metab"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-00448"},{"key":"e_1_3_4_71_2","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial","volume":"6","author":"Eggermont A.M.M.","year":"2020","unstructured":"Eggermont A.M.M., Kicinski M., Blank C.U., Mandala M., Long G.V. et al: Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2020; 6: 519.","journal-title":"JAMA Oncol"},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.001"},{"key":"e_1_3_4_73_2","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study","volume":"35","author":"Hsu C.","year":"2017","unstructured":"Hsu C., Lee S.H., Ejadi S., Even C., Cohen R.B. et al: Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study. J Clin Oncol 2017; 35: 4050.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_74_2","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/S1470-2045(20)30110-8","article-title":"Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study","volume":"21","author":"Huang J.","year":"2020","unstructured":"Huang J., Xu J., Chen Y., Zhuang W., Zhang Y. et al: Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Lancet Oncol 2020; 21: 832.","journal-title":"Lancet Oncol"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30104-3"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00175-3"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01896"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw640"},{"key":"e_1_3_4_80_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0545-2"},{"key":"e_1_3_4_81_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0384"},{"key":"e_1_3_4_82_2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.jtho.2018.11.028","article-title":"Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation","volume":"14","author":"Yang J.C.","year":"2019","unstructured":"Yang J.C., Gadgeel S.M., Sequist L.V., Wu C.L., Papadimitrakopoulou V.A. et al: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol 2019; 14: 553.","journal-title":"J Thorac Oncol"},{"key":"e_1_3_4_83_2","first-page":"22","article-title":"Clinical efficacy and safety of anti PD-1\/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer","volume":"45","author":"Zayas-Soriano M.","year":"2020","unstructured":"Zayas-Soriano M., Bonete-Sanchez M., Campillo-Lopez J., Marcos-Ribes B., Hernandez-Guio A. et al: Clinical efficacy and safety of anti PD-1\/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer. Farm Hosp 2020; 45: 22.","journal-title":"Farm Hosp"},{"key":"e_1_3_4_84_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0683"},{"key":"e_1_3_4_85_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0114-2"},{"key":"e_1_3_4_86_2","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.21.02618","article-title":"Pre-existing Thyroid Autoimmunity and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study of US Active-Duty Personnel","author":"McLeod D.S.A.","year":"2022","unstructured":"McLeod D.S.A., Bedno S.A., Cooper D.S., Hutfless S.M., Ippolito S. et al: Pre-existing Thyroid Autoimmunity and Risk of Papillary Thyroid Cancer: A Nested Case-Control Study of US Active-Duty Personnel. J Clin Oncol: JCO2102618 2022; .","journal-title":"J Clin Oncol: JCO2102618"},{"key":"e_1_3_4_87_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1292"},{"key":"e_1_3_4_88_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706509104"},{"key":"e_1_3_4_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2021.100194"},{"key":"e_1_3_4_90_2","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/bs.acr.2019.03.003","article-title":"Co-stimulatory and co-inhibitory pathways in cancer immunotherapy","volume":"143","author":"O'Neill R.E.","year":"2019","unstructured":"O'Neill R.E. and Cao X.: Co-stimulatory and co-inhibitory pathways in cancer immunotherapy. Adv Cancer Res 2019; 143: 145.","journal-title":"Adv Cancer Res"}],"container-title":["Computational and Structural Biotechnology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022001751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2001037022001751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/spj.science.org\/doi\/pdf\/10.1016\/j.csbj.2022.05.019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T13:01:40Z","timestamp":1779022900000},"score":1,"resource":{"primary":{"URL":"https:\/\/spj.science.org\/doi\/10.1016\/j.csbj.2022.05.019"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":89,"alternative-id":["10.1016\/j.csbj.2022.05.019"],"URL":"https:\/\/doi.org\/10.1016\/j.csbj.2022.05.019","relation":{},"ISSN":["2001-0370"],"issn-type":[{"value":"2001-0370","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunction","name":"articletitle","label":"Article Title"},{"value":"Computational and Structural Biotechnology Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.csbj.2022.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.","name":"copyright","label":"Copyright"}]}}